psilocybin (TRP-8802) / Tryp Therap - LARVOL DELTA

Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS) (clinicaltrials.gov) - P2 | N=14 | Recruiting | Sponsor: TRYP Therapeutics | Trial completion date: Feb 2025 ➔ Mar 2026 | Trial primary completion date: Feb 2025 ➔ Mar 2026

Trial completion date • Trial primary completion date • Gastrointestinal Disorder

Evaluation of Psilocybin (TRP-8802) in the Treatment of Binge Eating Disorder (clinicaltrials.gov) - P2 | N=5 | Completed | Sponsor: TRYP Therapeutics | Active, not recruiting ➔ Completed | Phase classification: P2a ➔ P2 | N=10 ➔ 5 | Trial completion date: Aug 2025 ➔ Jun 2024

Enrollment change • Phase classification • Trial completion • Trial completion date • Binge Eating Disorder • CNS Disorders

Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS) (clinicaltrials.gov) - P2 | N=14 | Recruiting | Sponsor: TRYP Therapeutics | Not yet recruiting ➔ Recruiting

Enrollment open • Gastrointestinal Disorder • CRP • IL6 • TNFA

Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS) (clinicaltrials.gov) - P2 | N=14 | Not yet recruiting | Sponsor: TRYP Therapeutics

New P2 trial • Gastrointestinal Disorder • CRP • IL6 • TNFA